TY  - JOUR
T1  - SCreening for osteoporosis in men receiving androgen deprivation therapy
AU  - Alibhai SH, Yun L, Cheung AM, Paszat L
Y1  - 2012/01/18
N1  - 10.1001/jama.2011.2022
JO  - JAMA
SP  - 255
EP  - 256
VL  - 307
IS  - 3
N2  - 
To the Editor: Prostate cancer is the most common cancer in men.1 One in 2 men with prostate cancer is expected to receive androgen deprivation therapy (ADT). Use of ADT is associated with accelerated bone loss and an increased risk of fractures.2 To better characterize fracture risk and optimize bone health, a bone mineral density (BMD) test has been recommended prior to ADT initiation since 2006 in Canada3 and elsewhere.4 Low rates of BMD use have been reported by single centers.5 We examined the rate of BMD testing in men starting ADT in the province of Ontario, Canada, between 1995 and 2008.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2011.2022
UR  - http://dx.doi.org/10.1001/jama.2011.2022
ER  -